Skip to content

Celcuity CELC Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead Sciences logo
Gilead SciencesGILD
$166M-34.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$5.76M+4,132%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$17.61M+880,150%
CG Oncology logo
CG OncologyCGON
$391.55M+57,312%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$722K-108%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's stock issuance proceeds?
Celcuity (CELC) reported stock issuance proceeds of $206K in Q1 2026.
What is the long-term trend for Celcuity's stock issuance proceeds?
Over 2 years (2022 to 2024), Celcuity's stock issuance proceeds has grown at a 124.8% compound annual growth rate (CAGR), from $152.41K to $770K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.